NCT04822818View on ClinicalTrials.gov

EFFICACY and SAFETY OF BEVACIZUMAB (ZIRABEV®) IN PATIENTS WITH SEVERE HYPOXEMIC COVID-19

PHASE3CompletedINTERVENTIONAL
Enrollment

96

Participants

Timeline

Start Date

April 17, 2021

Primary Completion Date

April 10, 2022

Study Completion Date

July 11, 2022

Conditions
Corona Virus InfectionSARS (Severe Acute Respiratory Syndrome)Virus DiseasesCoronaviridae InfectionsNidovirales InfectionsRNA Virus InfectionsRespiratory Tract InfectionsRespiratory Tract Diseases
Interventions
DRUG

BEVA+SOC

Bevacizumab : 7.5 mg / kg (with a maximum of 750 mg) on day 1 (D1) SOC : patients will receive the best of standard of care including corticosteroids, anticoagulant, antibiotics and tociluzimab

DRUG

SOC

patients will receive the best of standard of care including corticosteroids, anticoagulant, antibiotics and tociluzimab

Trial Locations (1)

Unknown

Hôpital TENON, Paris

All Listed Sponsors
lead

Assistance Publique - Hôpitaux de Paris

OTHER